search icon
      blog search icon

      Aridis Pharmaceuticals, Inc. (ARDS) stock rises in premarket: Here’s Why - Stocks Telegraph

      By Muhammad Ali

      Published on

      December 30, 2021

      1:36 PM UTC

      Aridis Pharmaceuticals, Inc. (ARDS) stock rises in premarket: Here’s Why - Stocks Telegraph

      Shares of the Aridis Pharmaceuticals, Inc. (ARDS) stock were rising in the premarket trading session today on December 30, 2021. ARDS stock price saw a push of 6.93% to reach $2.16 a share at the time of this writing. The stock was gloomy in the previous trading session and went down by 7.76% at closing. Let’s take a closer look at ARDS stock to understand the current bullish sentiment.

      What’s Happening?

      ARDS stock has captivated the attention of the investors today, however, there seems to be no stock-specific news in today’s date. No press release or any announcement by Aridis Pharmaceuticals today. No analyst has upgraded or increased the per-share target price of the stock. From the social media analysis, it seems that the discussions among investors in the social media platforms are driving the per-share price of the ARDS stock. At this point, it is better to discuss some recent events of Aridis Pharmaceuticals to understand more of it.

      Recent News of ARDS stock:

      Recently on December 21, 2021, Stuart Varney, on Fox Business interviewed the CEO of Aridis Pharmaceuticals. The CEO discussed Monoclonal Antibody Cocktail Protection Against COVID-19 Omicron Variant and Other Viruses there. The key points are given below.

      AR-703, a component of the AR-701 cocktail, attaches to the ‘S2’ stalk region of coronavirus spike proteins. It also ties with the Omicron variant with no loss in affinity when compared with the original virus.

      AR-701 shows broad, potent neutralization against all the variants of SARS-CoV-2. Moreover, the data suggest the board efficacy of the AR-701.

      Financial View of ARDS stock:

      In the previous month, ARDS announced third quarter 2021 financial results according to which

      The company generated $0.4 million in grant revenue in the third quarter of 2021 as compared to no revenue in the same period of the previous year. Net interest income in the third quarter of 2021 was reduced by nearly $5000 from $6000 approximately in the same quarter of last year. The company spent   $19.8 million in research and development expenses and $1.7 million in general and administrative expenses. These expenses were $4.2 million and $1.6 million respectively in the same tenure of the previous year. Net loss of the ARDS stock was $21.0 million, or $1.94 per share in the recently reported quarter.

      Wrap Up:

      So far so good for ARDS stock as far as market sentiment is concerned. From the investment perspective, deep fundamental, as well as sentiment analysis, is necessary before making any decision.

      More From Stocks telegraph